Trial Profile
Phase I Study of Inhaled Vidaza in Patients With Advanced NSCLC
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 05 Feb 2020 Status changed from recruiting to completed.
- 10 Sep 2019 Results (n=8) presented at the 20th World Conference on Lung Cancer